Health
Johnson & Johnson vaccine has 66% efficiency in one dose – Open Access Government
New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose – with a normal 85% efficiency
In promising new results from Phase Three, the American Johnson & Johnson vaccine appears to be a strong candidate for Emergency Use Approval. The company will apply for approval in the US by early February.
The UK has a contract to buy 30 million doses, with the US set to receive 100 million. The company is attempting to make a billion doses.
This news comes after the EU approved AstraZeneca for use, after a tense period of accusation and regulatory action.
The ENSEMBLE study
The vaccine trial,…
-
Noosa News9 hours agoConsolidated Pastoral Company buys Beetaloo aggregation in historic deal worth more than $300m
-
General23 hours agoAnthony Albanese condemns Bondi Beach terror attack as ‘act of evil antisemitism’
-
General24 hours agoThe mysterious assailants at Bondi
-
Business20 hours agoWhat Warren Buffett’s latest portfolio moves say about the market